Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Adjuvant Therapy in High-Risk PD-L1–Selected MIBC After Cystectomy
CTR20160680Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in urothelial carcinoma (MIBC), sponsored by Roche. Started Sep 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (MIBC)
Beyond the preview
Go deeper on CTR20160680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160680.